We can’t show the full text here under this license. Use the link below to read it at the source.
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
How Diabetes Drugs Affect Muscle and Fat Levels in People
AI simplified
Abstract
In over half of the studies reviewed, the proportion of reduction ranged between 20% and 50% of total weight lost.
- Weight loss from glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) is primarily due to reduction.
- Significant variability exists among studies regarding the impact of these therapies on body composition.
- Lean body mass loss is observed alongside weight loss from both GLP-1RAs and SGLT2is, similar to effects seen with diet and bariatric surgery.
- No significant differences were noted between GLP-1RAs and SGLT2is in terms of body composition changes.
- Attention is needed to strategies that preserve skeletal muscle and enhance physical function during weight loss treatments.
AI simplified
Key numbers
20% to 50%
Contribution to Weight Loss
Proportion of weight loss attributed to across various studies.
2.5 kg
Weight Loss with Canagliflozin
Weight loss after 26 weeks of treatment with canagliflozin.
4.5 kg
Weight Loss with Dapagliflozin
Total weight loss after 104 weeks of dapagliflozin therapy.